Faisal Khurshid
Stock Analyst at Leerink Partners
(4.27)
# 444
Out of 5,043 analysts
26
Total ratings
61.9%
Success rate
16.21%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $31.25 | +28.00% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $11.09 | +80.42% | 1 | Sep 25, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $75.28 | -3.03% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $2.03 | -1.66% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $110.17 | -7.42% | 2 | Jul 10, 2025 | |
| ABCL AbCellera Biologics | Assumes: Outperform | $5 | $5.80 | -13.72% | 1 | Jul 7, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $1.65 | -39.39% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $24.38 | +84.58% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $11.88 | +34.68% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.78 | +12.68% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.98 | +1,526.02% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 | $61.14 | -1.86% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $93.21 | -14.17% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $3.98 | +276.88% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $7 | $10.51 | -33.40% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.47 | +157.66% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.27 | +451.18% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.41 | +48.01% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.83 | +502.85% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $5.93 | +85.50% | 1 | Mar 21, 2023 |
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $31.25
Upside: +28.00%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $11.09
Upside: +80.42%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $75.28
Upside: -3.03%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $2.03
Upside: -1.66%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $110.17
Upside: -7.42%
AbCellera Biologics
Jul 7, 2025
Assumes: Outperform
Price Target: $5
Current: $5.80
Upside: -13.72%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $1.65
Upside: -39.39%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $24.38
Upside: +84.58%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $11.88
Upside: +34.68%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.78
Upside: +12.68%
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $0.98
Upside: +1,526.02%
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $61.14
Upside: -1.86%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $93.21
Upside: -14.17%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $3.98
Upside: +276.88%
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $10.51
Upside: -33.40%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.47
Upside: +157.66%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.27
Upside: +451.18%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.41
Upside: +48.01%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.83
Upside: +502.85%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $5.93
Upside: +85.50%